Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2017, Article ID 5932675, 13 pages
Research Article

Cost of Living with Parkinson’s Disease over 12 Months in Australia: A Prospective Cohort Study

1Centre for Population Health Research, School of Health & Social Development, Faculty of Health, Deakin University, Burwood, VIC 3125, Australia
2Clinical Research Centre for Movement Disorders and Gait, The National Parkinson Foundation Centre of Excellence, Kingston Centre, Monash Health, Cheltenham, VIC 3192, Australia
3School of Clinical Sciences Monash University, Clayton, VIC 3168, Australia
4Healthscope, Northpark Private Hospital, Plenty and Greenhills Roads, Bundoora, VIC 3083, Australia
5School of Allied Health, La Trobe University, Bundoora, VIC 3083, Australia

Correspondence should be addressed to Jennifer J. Watts; ua.ude.nikaed@sttaw.j

Received 2 November 2016; Accepted 19 January 2017; Published 2 March 2017

Academic Editor: Antonio Pisani

Copyright © 2017 Shalika Bohingamu Mudiyanselage et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Parkinson disease (PD) is a costly chronic condition in terms of managing both motor and nonmotor symptoms. The burden of disease is high for individuals, caregivers, and the health system. The aim of this study is to estimate the annual cost of PD from the household, health system, and societal perspectives. Methods. A prospective cohort study of newly referred people with PD to a specialist PD clinic in Melbourne, Australia. Participants completed baseline and monthly health resource use questionnaires and Medicare data were collected over 12 months. Results. 87 patients completed the 12-month follow-up assessments. The mean annual cost per person to the health care system was $32,556 AUD. The burden to society was an additional $45,000 per annum per person with PD. The largest component of health system costs were for hospitalisation (69% of total costs). The costs for people with moderate to severe disease were almost 4 times those with mild PD ($63,569 versus $17,537 ). Conclusion. PD is associated with significant costs to individuals and to society. Costs escalated with disease severity suggesting that the burden to society is likely to grow with the increasing disease prevalence that is associated with population ageing.